Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
Ann Hematol. 2018 May;97(5):923.
doi: 10.1007/s00277-018-3277-x.
10 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
11 Hospital Clínico San Carlos, Madrid, Spain.
12 Hospital Universitario Virgen del Rocío, Sevilla, Spain.
13 Department of Medicine, University of Valencia, Valencia, Spain.
14 Hematology Department, Hospital Universitari i Politècnic, La Fe, Avinguda Fernando Abril Martorell, 106, 46026, València, Spain. montesinos_pau@gva.es.
15 CIBERONC, Instituto Carlos III, Madrid, Spain. montesinos_pau@gva.es.
The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández in the original article.The original version of this article was revised: The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández.